Analysts Set Evolent Health, Inc (NYSE:EVH) Target Price at $15.85

Shares of Evolent Health, Inc (NYSE:EVH) have received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.8462.

EVH has been the subject of a number of analyst reports. Zacks Research lowered Evolent Health from a “hold” rating to a “strong sell” rating in a report on Friday, October 10th. Truist Financial raised their price target on Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evolent Health in a report on Tuesday, September 9th. BTIG Research reiterated a “buy” rating and issued a $20.00 price objective on shares of Evolent Health in a research report on Tuesday, September 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research report on Saturday.

Institutional Investors Weigh In On Evolent Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its position in shares of Evolent Health by 88.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after buying an additional 1,194 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Evolent Health in the first quarter worth $25,000. Parallel Advisors LLC raised its position in shares of Evolent Health by 82.6% in the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock worth $39,000 after buying an additional 1,577 shares in the last quarter. Strs Ohio purchased a new stake in shares of Evolent Health in the first quarter worth $47,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Evolent Health in the second quarter worth $58,000.

Evolent Health Price Performance

Evolent Health stock opened at $7.82 on Wednesday. Evolent Health has a one year low of $7.06 and a one year high of $25.22. The business has a fifty day moving average price of $8.71 and a 200-day moving average price of $9.24. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market capitalization of $918.34 million, a P/E ratio of -4.85 and a beta of 0.66.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Tuesday, June 4th. The technology company reported $0.21 EPS for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The firm had revenue of $427.70 million during the quarter. As a group, equities research analysts forecast that Evolent Health will post 0.08 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.